Next Article in Journal / Special Issue
The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials
Previous Article in Journal / Special Issue
Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
Article Menu

Export Article

Open AccessFeature PaperReview
Biomedicines 2016, 4(4), 25; doi:10.3390/biomedicines4040025

Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools

Department of Medical Radiation Physics, Lund University, 221 85 Lund, Sweden
*
Author to whom correspondence should be addressed.
Academic Editor: Benjamin Franc
Received: 12 September 2016 / Revised: 7 November 2016 / Accepted: 8 November 2016 / Published: 15 November 2016
(This article belongs to the Special Issue Molecular Imaging as a Tool for Personalized Medicine)
View Full-Text   |   Download PDF [5722 KB, uploaded 15 November 2016]   |  

Abstract

For treatment of systemic malignancies, when external radiation therapy is not applicable, radionuclide therapy can be an alternative. In this form of therapy, radionuclides are administered to the patient, often in a form where the radionuclide is labelled to a molecule that plays the active part in the localization of the tumor. Since the aim is to impart lethal damage to tumor cells while maintaining possible side-effects to normal tissues at tolerable levels, a proper and accurate personalized dosimetry should be a pre-requisite. In radionuclide therapy, there is a need to measure the distribution of the radiopharmaceutical in vivo, as well as its re-distribution over time, in order estimate the total energy released in radioactive decays and subsequent charged-particle interactions, governing the absorbed dose to different organs and tumors. Measurements are usually performed by molecular imaging, more specifically planar and SPECT (Single-Photon Emission Computed Tomography) imaging, combined with CT. This review describes the different parts in the dosimetry chain of radionuclide therapy. Emphasis is given to molecular imaging tools and the requirements for determining absorbed doses from quantitative planar and SPECT images. As example solutions to the different problems that need to be addressed in such a dosimetric chain, we describe our tool, Lundadose, which is a set of methods that we have developed for personalized dosimetry. View Full-Text
Keywords: dosimetry; radionuclide therapy; SPECT; reconstruction; quantification; Monte Carlo dosimetry; radionuclide therapy; SPECT; reconstruction; quantification; Monte Carlo
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ljungberg, M.; Sjögreen Gleisner, K. Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools. Biomedicines 2016, 4, 25.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top